Supplementary Methods, Supplementary Figure 1-8, Supplementary Table 1 from The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Methods: Fluorescence in situ hybridization (FISH); MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) enzymatic conversion assay; Western blot analysis; Multiparametric flow cytometry; Table S1. List of the antibodies used for multiparametric flow cytometry; Degranulation assay; Proliferation assay; Cytotoxicity assays; Cytokine measurements; Animal experiments; Figure S1. Different sensitivity to ibrutinib in hematological cell lines; Figure S2. MCL-RL engrafted mice: tumor burden and histology; Figure S3. CTL019 design and production; Figure S4. CTL019 cell production from primary MCL samples; Figure S5. Effect of ibrutinib in T cell function in vitro and in vivo; Figure S5. Effect of ibrutinib in T cell function in vitro and in vivo. A. CTL019 proliferation assay in the presence of ibrutinib;Figure S6. Peripheral blood T cell subsets in mice treated with CART19 or CART19-ibrutinib; Figure S7. CXCR4 and inhibitory/costimulatory receptor expression in peripheral blood of mice treated with CART19 or CART19-ibrutinib; Figure S8. A. Ibrutinib did not enhance the anti-tumor activity of control untransduced T cells.
Authors: Marco Ruella, Saad S. Kenderian, Olga Shestova, Joseph A. Fraietta, Sohail Qayyum, Qian Zhang, Marcela V. Maus, Xiaobin Liu, Selene Nunez-Cruz, Michael Klichinsky, Omkar U. Kawalekar, Michael Milone, Simon F. Lacey, Anthony Mato, Stephen J. Schuster, Michael Kalos, Carl H. June, Saar Gill, Mariusz A. Wasik
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361883922